Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KHK | P50053 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9321491 | 0.83 | KEAP1 (0.41) | KEAP1NFE2L2ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL29260193 | 0.81 | KEAP1 (0.56) | KEAP1NFE2L2KHK | |
| SCHEMBL25036382 | 0.76 | GLP1R (0.34) | — | |
| SCHEMBL12090788 | 0.76 | PIK3CA (0.34) | ALDH1A1POLBKMT2ACYP1A2 | |
| SCHEMBL23673393 | 0.74 | ALDH1A1 (0.33) | KEAP1NFE2L2ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL23673396 | 0.74 | ERBB2 (0.33) | KEAP1NFE2L2 | |
| SCHEMBL23694779 | 0.74 | CYP1A2 (0.40) | KEAP1NFE2L2ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL2561658 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MAPK1SMN1; SMN2POLBKMT2A | |
| SCHEMBL6222738 | 0.74 | KEAP1 (0.50) | KEAP1NFE2L2KHKKMT2A | |
| SCHEMBL20303036 | 0.73 | SMN1; SMN2 (0.38) | KEAP1NFE2L2ALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0187376-A2 | 6,7-Disubstituted 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids | BAYER AG (DE) | 1986-07-16 | — | — | EP | claimed |
| EP-4273135-A1 | PLASMIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-9932346-B2 | Pyrrolopyrimidines for use in influenza virus infection | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-03 | — | — | US | disclosed |
| US-20170253600-A1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-09-07 | — | — | US | disclosed |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| US-9650375-B2 | Indole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP. (US) | 2017-05-16 | — | — | US | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-1807421-B1 | 2-AMIDO-4-PHENYLTHIAZOLE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2011-03-16 | — | — | EP | disclosed |
| US-7842671-B1 | Peptidomimetic inhibitors of STAT activity and uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-11-30 | — | — | US | disclosed |
| US-20070225282-A1 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| EP-1192138-A1 | METHOD FOR THE PRODUCTION OF 2,6-DICHLORO-5-FLUORO-NICOTINIC ACID AND COARSE AND PARTICULARLY PURE 2,6-DICHLORO-5-FLUORO-NICOTINIC ACID | Bayer Aktiengesellschaft (DE) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076978-A1 | METHOD FOR THE PRODUCTION OF 2,6-DICHLORO-5-FLUORO-NICOTINIC ACID AND COARSE AND PARTICULARLY PURE 2,6-DICHLORO-5-FLUORO-NICOTINIC ACID | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-21 | — | — | WO | disclosed |
| US-5334724-A | Preparation of substituted 2-chloropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1994-08-02 | — | — | US | disclosed |
| EP-0438691-B1 | Process for the preparation of substituted 2-chloropyridines | BAYER AG (DE) | 1994-02-16 | — | — | EP | disclosed |
| EP-0187376-B1 | 6,7-DISUBSTITUTED 1-CYCLOPROPYL-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACIDS | BAYER AG (DE) | 1992-05-13 | — | — | EP | disclosed |
| EP-0438691-A1 | Process for the preparation of substituted 2-chloropyridines | BAYER AG (DE) | 1991-07-31 | — | — | EP | disclosed |
| EP-0333020-A2 | Process for the preparation of substituted pyridines | ABBOTT LABORATORIES (US) | 1989-09-20 | — | — | EP | disclosed |
| US-4840954-A | BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-20 | — | — | US | disclosed |
| EP-0187376-A2 | 6,7-Disubstituted 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids | BAYER AG (DE) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225282-A1 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | F2, F11, TBXAS1 | KEAP1 1054/4885NFE2L2 742/4885ALDH1A1 3141/4885 |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | IDO1, IDO2, INMT | KEAP1 1948/4885NFE2L2 1440/4885ALDH1A1 143/4885 |
| US-20170253600-A1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | IMPDH1, IMPDH2, TYMP | KEAP1 2951/4885NFE2L2 2084/4885ALDH1A1 211/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | KEAP1 853/4885NFE2L2 1532/4885ALDH1A1 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.